Description
Upon the establishment and improvement of China Drug Supervision and Administration System, the global biomedical industry value chain has been shifting towards the biotech industry zones in China. The fastest-growing biomedical market portfolio in China is expected to be dominated by monoclonal antibody, gene therapeutics and vaccines for anti-infection and anti-cancer diagnostics and therapeutics.
From a long-term sustainable perspective, it is highly suggested that the issues on how to strategically capture and leverage the emerging opportunities in anti-cancer and anti-infection diagnostics and therapeutics be well illustrated on such a platform.
CHINA BIOMEDICAL INNOVATIONS CONFERENCE 2009 will feature a thriving conference program, incorporating intensive onsite demonstration, dedicated anti-cancer & stem cell biology workshop and interactive business partnership salon.
